Ahmedabad, India, 23 October 2026: Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a U.S.-based global biopharmaceutical company, today, inaugurated its new administrative office in Ahmedabad, supporting its teams in India and strengthening collaboration across its global business.
The new office represents a project investment of approximately INR 135 crore (US$15 million). Located on Cliantha Road, Ahmedabad, the new office spans approximately 3.35 lakh square feet and will accommodate approximately 1,200 employees. Designed to support Amneal’s expanding workforce, the facility will bring key teams together, strengthen collaboration and provide additional infrastructure for the company’s operations in India.
Over the years, Amneal has steadily expanded its capabilities in India across manufacturing, research and development, quality and commercial operations, including its commercial office in Mumbai. These operations are an integral part of Amneal’s global network, which spans the United States, India and Ireland. This August, the company acquired Kashiv BioSciences, further expanding Amneal’s global biosimilar development and manufacturing capabilities.
“This new Ahmedabad office reflects Amneal’s continued investment in the people and capabilities that support its global business. India is an important part of our network, complementing our significant and growing U.S. manufacturing footprint,” said Chirag Patel, co-founder and co-chief executive officer of Amneal. “Across our operations, we are investing in scientific expertise, manufacturing and infrastructure to support sustainable growth and expand access to high-quality, affordable medicines.”
“Our colleagues in India play an important role in advancing Amneal’s research, development, manufacturing and business operations,” said Chintu Patel, co-founder and co-chief executive officer of Amneal. “This new office brings key teams together in a space designed to support collaboration and their continued development. By connecting our people and expertise across our global network, we can strengthen execution, advance increasingly complex medicines and better serve patients.”
Amneal is also advancing plans for two greenfield manufacturing facilities in Gujarat focused on peptide synthesis and sterile fill-finish manufacturing. These projects are part of the company’s broader investment in capabilities to support its future portfolio.
The new office supports Amneal’s broader strategy to strengthen its global capabilities and expand access to high-quality, affordable medicines.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.
